Aspen Neuroscience (ASPE) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspen Neuroscience is the larger company by market cap ($361.2 million vs $340.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASPE | CTNM |
|---|---|---|
| Share price | $12.42 | $8.68 |
| Market cap | $361.16M | $340.83M |
| 1-day change | +0.24% | -3.98% |
| YTD return | — | -24.06% |
| 1-year return | — | -20.69% |
| EPS (TTM) | $-4.89 | $-1.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-59.98M |
| 52-week high | $14.90 | $17.79 |
| 52-week low | $11.20 | $6.73 |
| Distance from 52-week high | -16.64% | -51.19% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +146.89% |
| Average volume | 352.42K | 776.03K |
| Shares outstanding | 29.08M | 35.35M |
| Employees | 120 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspen Neuroscience
ASPE stock →Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ASPE vs CTNM FAQ
Which is bigger, Aspen Neuroscience or Contineum Therapeutics?
Aspen Neuroscience (ASPE) is larger, with a market capitalization of $361.16M compared with $340.83M for Contineum Therapeutics (CTNM).
Are Aspen Neuroscience and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.